

Supporting Information for

3-(3,4-Dichlorophenyl)-5-(1*H*-indol-5-yl)-1,2,4-oxadiazole

Julia A. Efimova^{1,2}, Anton A. Shetnev^{1*}, Sergey V. Baykov³, Anél Petzer⁴, Jacobus P. Petzer⁴

¹ Pharmaceutical Technology Transfer Center, Yaroslavl State Pedagogical University named after K.D. Ushinsky, Yaroslavl, 150000, Russian Federation; a.shetnev@list.ru (A.A.S.); julia.efimova.555@gmail.com (J.A.E.);

² Department of organic chemistry, Russian State University named after A. N. Kosygin, Moscow, 115035, Russian Federation

³ Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, 199034, Russian Federation; s.baykov@spbu.ru (S.V.B.).



⁴ Pharmaceutical Chemistry and Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa; 12264954@nwu.ac.za (A.P.); jacques.petzer@nwu.ac.za (J.P.P.)

* Correspondence: a.shetnev@list.ru (A.A.S.)

Contents:

Copies of ¹H and ¹³C NMR spectra for compounds **2** and **4**

^1H and ^{13}C NMR spectra for 3-(3,4-dichlorophenyl)-5-(1*H*-indol-5-yl)-1,2,4-oxadiazole (**4**)



¹H NMR spectra for 3,4-dichlorobenzamidoxime (2)

